vs
ANI PHARMACEUTICALS INC（ANIP）与ASSOCIATED BANC-CORP（ASB）财务数据对比。点击上方公司名可切换其他公司
ASSOCIATED BANC-CORP的季度营收约是ANI PHARMACEUTICALS INC的1.6倍（$383.0M vs $247.1M），ASSOCIATED BANC-CORP净利率更高（31.2% vs 11.1%，领先20.1%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 9.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
联合银行集团（Associated Banc-Corp）是美国区域性银行控股公司，总部位于威斯康星州格林贝，深耕美国中西部地区，主营零售银行、商业银行、商业地产贷款、私人银行及特色金融服务，在威斯康星州、伊利诺伊州、明尼苏达州设有220多个营业网点，覆盖100多个社区，还在印第安纳、密歇根等多州设有贷款办事处。
ANIP vs ASB — 直观对比
营收规模更大
ASB
是对方的1.6倍
$247.1M
净利率更高
ASB
高出20.1%
11.1%
两年增速更快
ANIP
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $383.0M |
| 净利润 | $27.5M | $119.6M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | 31.2% |
| 营收同比 | 29.6% | — |
| 净利润同比 | 367.5% | 566.6% |
| 每股收益（稀释后） | $1.14 | $0.70 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPASB
| Q1 26 | — | $383.0M | ||
| Q4 25 | $247.1M | $310.0M | ||
| Q3 25 | $227.8M | $305.2M | ||
| Q2 25 | $211.4M | $300.0M | ||
| Q1 25 | $197.1M | $285.9M | ||
| Q4 24 | $190.6M | $270.3M | ||
| Q3 24 | $148.3M | $329.7M | ||
| Q2 24 | $138.0M | $321.8M |
净利润ANIPASB
| Q1 26 | — | $119.6M | ||
| Q4 25 | $27.5M | $137.1M | ||
| Q3 25 | $26.6M | $124.7M | ||
| Q2 25 | $8.5M | $111.2M | ||
| Q1 25 | $15.7M | $101.7M | ||
| Q4 24 | $-10.3M | $-161.6M | ||
| Q3 24 | $-24.2M | $88.0M | ||
| Q2 24 | $-2.3M | $115.6M |
营业利润率ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 52.6% | ||
| Q3 25 | 15.9% | 50.5% | ||
| Q2 25 | 6.6% | 46.5% | ||
| Q1 25 | 13.3% | 42.3% | ||
| Q4 24 | -2.3% | -65.8% | ||
| Q3 24 | -13.8% | 32.8% | ||
| Q2 24 | 3.7% | 32.0% |
净利率ANIPASB
| Q1 26 | — | 31.2% | ||
| Q4 25 | 11.1% | 44.2% | ||
| Q3 25 | 11.7% | 40.9% | ||
| Q2 25 | 4.0% | 37.1% | ||
| Q1 25 | 8.0% | 35.6% | ||
| Q4 24 | -5.4% | -59.8% | ||
| Q3 24 | -16.3% | 26.7% | ||
| Q2 24 | -1.7% | 35.9% |
每股收益（稀释后）ANIPASB
| Q1 26 | — | $0.70 | ||
| Q4 25 | $1.14 | $0.80 | ||
| Q3 25 | $1.13 | $0.73 | ||
| Q2 25 | $0.36 | $0.65 | ||
| Q1 25 | $0.69 | $0.59 | ||
| Q4 24 | $-0.45 | $-1.10 | ||
| Q3 24 | $-1.27 | $0.56 | ||
| Q2 24 | $-0.14 | $0.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $5.0B |
| 总资产 | $1.4B | $45.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
总债务ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $594.1M | ||
| Q2 25 | — | $593.5M | ||
| Q1 25 | — | $591.4M | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $844.3M | ||
| Q2 24 | — | $536.1M |
股东权益ANIPASB
| Q1 26 | — | $5.0B | ||
| Q4 25 | $540.7M | $5.0B | ||
| Q3 25 | $505.8M | $4.9B | ||
| Q2 25 | $436.8M | $4.8B | ||
| Q1 25 | $418.6M | $4.7B | ||
| Q4 24 | $403.7M | $4.6B | ||
| Q3 24 | $405.9M | $4.4B | ||
| Q2 24 | $455.8M | $4.2B |
总资产ANIPASB
| Q1 26 | — | $45.6B | ||
| Q4 25 | $1.4B | $45.2B | ||
| Q3 25 | $1.4B | $44.5B | ||
| Q2 25 | $1.3B | $44.0B | ||
| Q1 25 | $1.3B | $43.3B | ||
| Q4 24 | $1.3B | $43.0B | ||
| Q3 24 | $1.3B | $42.2B | ||
| Q2 24 | $920.8M | $41.6B |
负债/权益比ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $218.1M | ||
| Q3 25 | $44.1M | $158.0M | ||
| Q2 25 | $75.8M | $141.5M | ||
| Q1 25 | $35.0M | $98.2M | ||
| Q4 24 | $15.9M | $207.1M | ||
| Q3 24 | $12.5M | $105.1M | ||
| Q2 24 | $17.4M | $113.5M |
自由现金流ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — |
自由现金流率ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — |
资本支出强度ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — |
现金转化率ANIPASB
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.59× | ||
| Q3 25 | 1.66× | 1.27× | ||
| Q2 25 | 8.87× | 1.27× | ||
| Q1 25 | 2.23× | 0.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | — | 0.98× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ASB
| Net Interest Income | $307.2M | 80% |
| Noninterest Income | $75.9M | 20% |
